253
Views
9
CrossRef citations to date
0
Altmetric
Drug Evaluation

Travoprost/timolol fixed combination

, DO & , MD MBA
Pages 1059-1065 | Published online: 01 Apr 2008

Bibliography

  • Quigley HA. Number of people with glaucoma worldwide. Br J Ophthalmol 1996;80(5):389-93
  • Goldberg I. Relationship between intraocular pressure and preservation of visual field in glaucoma. Surv Ophthal 2003;48(Suppl 1):S3-7
  • Kass MA, Heuer DK, Higginbotham EJ, et al.; The Ocular Hypertension Treatment Study. A randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open angle glaucoma. Arch Ophthalmol 2002;120:71-13
  • Lichter PR, Musch DC, Gillespie BW, et al.; CIGTS Study Croup. Interim clinical outcomes in the Collaborative Initial Glaucoma Treatment Study comparing initial treatment randomized to medications or surgery. Ophthalmology 2001;108:1943-53
  • Collaborative Normal-Tension Glaucoma Study Group. Comparison of glaucomatous progression between untreated patients with normal-tension glaucoma and patients with therapeutically reduced intraocular pressures. Am J Ophthalmol 1998;126:487-97
  • Robin AL, Covert D. Does adjunctive glaucoma therapy affect adherence to the initial primary therapy? Ophthalmology 2005;112:487-97
  • Hoy SM, Keam SJ, Keating GM. Travoprost/timolol. Drugs Aging 2006;23:587-97
  • European Agency for the Evaluation of Medicinal Products. The morning or evening at the same time each day in DuoTrav: European Public Assessment Report (EPAR). Available from: http://www.emea.eu.int/
  • Bron AJ, Chidlow G, Melena J, Osborne NN. Beta-blocker in the treatment of glaucoma. In: Pharmacotherapy in Glaucoma. Orgul S, Flammer J, editors. Seattle: Verlag Hans Huber 2000. p. 79-113
  • Goldberg I, Cunha-Vaz J, Jakobsen JE, et al. Comparison of topical travoprost eye drops given once daily and timolol 0.5% given twice daily in patients with open-angle glaucoma or ocular hypertension. J Glaucoma 2001;10:414
  • Bazzaz S, Myers JS, Katz LJ. Travoprost in the treatment of glaucoma. Expert Rev Ophthalmol 2007;2(2):177-83
  • Allingham RR, Damji D, Freedman S, et al., (eds). Shields' Textbook of Glaucoma. Philadelphia, PA: Lippincott Williams & Wilkins; 2005. p. 471-83
  • Toris CB, Zhan GL, Camras CB, McLaughlin MA. Effects of travoprost on aqueous humor dynamics in monkeys. J Glaucoma 2005;140:1-7
  • Brubaker R, Schoff EO, Nau CB, et al. Effects of AGN 192024, a new ocular hypotensive agent, on aqueous dynamics. Am J Ophthalmol 2001;131:19
  • Ziai N, Dolan JW, Kacere RD, et al. The effects on aqueous dynamics of PhXA41, a new prostaglandin F2 alpha analogue, after topical application in normal and ocular hypertensive human eyes. Arch Ophthalmol 1993;111:1351
  • Toris CB, Zhan G, Fan S, et al. Effects of travoprost on aqueous humor dynamics in patients with elevated intraocular pressure. J Glaucoma 2007;16(2):189-95
  • Barnebey H, Orengo-Nania S, Flowers BE, et al. The safety and efficacy of travoprost 0.004%/timolol 0.5% fixed combination ophthalmic solution. Am J Ophthalmol 2005;140:1-7
  • Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005;140:242-50
  • Hughes BA, Bacharach J, Craven ER, et al. A three-month, multicenter, double-masked study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution and timolol 0.5% dosed concomitantly in subjects with open-angle glaucoma or ocular hypertension. J Glaucoma 2005;14:392-9
  • Henry JC, Kessler TL, Mallick S, et al.; Travoprost/timolol Study Group. Comparison of the safety and IOP-lowering efficacy of travoprost 0.004%/timolol 0.5% fixed combination to the concomitant administration of Xalatan and timolol 0.5% [abstr. 446]. ARVO, Fort Lauderdale; 2006
  • Topouzis F, Melamed S, Danesh-Mayer H, et al. A one-year study to compare the efficacy and safety of once-daily travoprost 0.004%/timolol 0.5% to once daily latanoprost 0.005%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. Eur J Ophthalmol 2007;17:183-90
  • Parrish RK, Palmberg P, Sheu WP. A comparison of latanoprost, bimatoprost, and travoprost in patients with elevated intraocular pressure: a 12-week randomized, masked-evaluator multicenter study. Am J Ophthalmol 2003;135:688-703
  • Netland PA, Landry T, Sullivan EK, et al. Travoprost compared with latanoprost and timolol in patients with open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2001;132:472-84
  • DuBiner HB, Sircy MD, Landry T, et al. Comparison of the diurnal ocular hypotensive efficacy of travoprost and latanoprost over a 44-hour period in patients with elevated intraocular pressure. Clin Ther 2004;26:35-47
  • Konstas AG, Vassilios PK, Ioannis EK, et al. Efficacy and safety of latanoprost versus travoprost in exfoliative glaucoma patients. Ophthalmology 2007;114:653-7
  • Denis P, Andrew R, Wells D, Friren B. A comparison of morning and evening instillation of a combination travoprost 0.004%/timolol 0.5% ophthalmic solution. Eur J Ophthalmol 2006;16:407-15
  • Konstas AG, Tsironi S, Vakalis AN, et al. 24-hour intraocular pressure control obtained with evening versus morning dosed travoprost/timolol maleate fixed combination in patients with open angle glaucoma. ARVO, Fort Lauderdale; 2007, Poster 5569/B908
  • Weinreb RN. Compliance with medical treatment of glaucoma. J Glaucoma 1992;1:134-6
  • Tsai JC, McClure CA, Ramos SE, et al. Compliance barriers in glaucoma: a systematic classification. J Glaucoma 2003;12:393-8
  • Patel SC, Spaeth GL. Compliance in patients prescribed eye drop for glaucoma. Ophthalmic Surg 1995;26:233-6
  • Chrai SS, Makoid MC, Eriksen SP, Robinson JR. Drop size and initial dosing frequency problems of topically applied ophthalmic drugs. J Pharm Sci 1974;63:333-8
  • Ventura MP, Saheb NE, Solari HP, et al. Cost considerations of the new fixed combinations for glaucoma medical therapy. J Clin Pharm Ther 2005;30:251-4
  • Noecker RJ, Herrygers LA, Anwaruddin R. Corneal and conjunctival changes caused by commonly used glaucoma medications. Cornea 2004;23:490-6
  • Gasset AR, Ishii Y, Kaufman HE, et al. Cytotoxicity of ophthalmic preservatives. Am J Ophthalmol 1974;78:98-105
  • Mietz H, Niesen U, Kriegelstein GK. The effects of preservatives and antiglaucomatous medication on histopathology of the conjunctiva. Graefes Arch Clin Exp Ophthalmol 1994;232:561-5

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.